A fact sheet on the TB skin test, including information on latent TB infection, TB disease, and what a positive/negative skin test means. The fact sheet also has information on testing after receiving the BCG vaccine.
This serial presents updated guidelines to US public health officials, healthcare providers, and laboratory workers for use of FDA-approved interferon gamma release assays (IGRAs) to diagnose both active and latent TB infection in adults and children. These guidelines include use of the QuantiFERON-TB Gold In-Tube Test (QFT-GIT) and the T-SPOT.TB Test (T-Spot), two new IGRAs that were not included in the previous guidelines published in 2005. The antigens, methods, and interpretation criteria for these assays differ from those for IGRAs approved previously.
This report provides data on the mortality among patients with TB and associations with HIV infection. To investigate the impact of HIV on risk for death during TB treatment in the United States, data were analyzed for all culture-positive patients with TB from 1993 to 2008. The proportion that died was determined and stratified by HIV test result. Mortality data were restricted to patients reported before 2007.
This series of patient education fact sheets provides information on drugs used in the treatment of TB (e.g., Clofazimine, Ethambutol, Ethionamide, Isoniazid, Levofloxacin, Moxifloxacin, PASER [p-aminosalicylic acid granules], Pyrazinamide, Pyridoxine, Rifabutin, Rifampin, Streptomycin). The fact sheets include information on medication side effects, actions to take if side effects occur, and instructions in the event a dose of medication is missed.
Dr. Mark Gilbert of the BC Centre for Disease Control talks about tuberculosis in a minute-long video.
An infographic with information on latent TB, TB disease, TB in British Columbia, TB globally, and TB symptoms,
This report presents results from the U.S. National TB Surveillance System for 2009. It states that 11,540 TB cases were reported in the United States in 2009, for a rate of 3.8 cases per 100,000 population. This was a decrease of 11.4 percent from the rate of 4.2 per 100,000 reported in 2008. Also, this was the lowest recorded rate since the beginning of national TB surveillance in 1953, and the greatest single-year decrease ever recorded.
This report discusses the results from the National TB Surveillance System for 2009. A total of 11,540 TB cases were reported in the United States for a TB rate of 3.8 cases per 100,000 population. This was a decrease of 11.4 percent from the rate of 4.2 per 100,000 reported for 2008. This rate was the greatest single-year decrease ever recorded and the lowest recorded rate since national TB surveillance began in 1953.
This report summarizes the National Tuberculosis Indicators Project (NTIP) results from 2002-2008, the most recent five-year period for which data are available. NTIP is a secure, web-based monitoring system that uses routinely collected surveillance data on individual TB cases to measure performance of state and local TB programs, help programs prioritize improvement efforts and focus on key TB control activities, and track progress toward national program objectives. Results show that TB program performance was mixed for this period.
This report discusses the CDC launch of the TB Genotyping Information Management System (TB GIMS), to improve dissemination of data to state and local health officers, including TB controllers. TB GIMS builds upon the established infrastructure of CDC’s National Tuberculosis Surveillance System (NTSS) and incorporates genotype data to create a centralized database and reporting system of patient-level results to generate local and national TB cluster-level reports, tables, and maps.
